Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TMF switch versus continued entecavir in chronic hepatitis B with low-level viremia after prior entecavir treatment
ChiCTR2300069493Phase 4Recruiting
- Sponsor
- The 2nd Affiliated Hospital of Chongqing Medical University
- Start
- Jan 2023
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tenofovir + amibufenamide and entecavir in Chronic Hepatitis B (CHB) (2 arms), sponsored by The 2nd Affiliated Hospital of Chongqing Medical University. Primary endpoint: Serum hepatitis B virus DNA. Started Jan 2023; status: recruiting.
02
Drugs
tenofovir + amibufenamideentecavir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR2300069493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069493.